trending Market Intelligence /marketintelligence/en/news-insights/trending/LloXDQPExepn--68eeQu0w2 content esgSubNav
In This List

Fate Therapeutics closes common stock offering

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Fate Therapeutics closes common stock offering

Fate Therapeutics Inc. closed its underwritten public offering of 10,953,750 common shares at $4.20 apiece with gross proceeds of about $42.9 million.

The shares sold included the full exercise of the underwriters' option to buy 1,428,750 additional shares.

Net proceeds will be used for clinical development and research activities, working capital and other general corporate purposes.

Leerink Partners LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as a co-manager for the offering.